The total return over the past 12 months is +32.51% vs. +16.94% for the S&P 500. So far it's up -34.50% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +32.51% | +31.17% | (12.32%) | N/A | N/A | N/A |
| Total Return CAGR | +32.51% | +31.17% | (12.32%) | N/A | N/A | N/A |
| Revenue CAGR | (83.86%) | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | (766.65%) | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | (826.67%) | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | (234.49%) | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | (186.84%) | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Monte Rosa Therapeutics, Inc. (GLUE)
| Year | Start price | End price | GLUE Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $15.68 | $10.27 | (34.50%) | +14.51% | (49.01%) |
| 2025 | $6.94 | $15.68 | +125.94% | +17.72% | +108.22% |
| 2024 | $5.65 | $6.94 | +22.83% | +24.89% | (2.06%) |
| 2023 | $7.61 | $5.65 | (25.76%) | +26.19% | (51.95%) |
| 2022 | $20.42 | $7.61 | (62.73%) | (18.17%) | (44.56%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
